Using bevacizumab to treat metastatic cancer: UK consensus guidelines

British Journal of Hospital Medicine

Volumn 71, Issue 12, 2010, Pages 670-677

  Miles, D ^a   Bridgewater, J ^b   Ellis, P ^c   Harrison, M ^a   Nathan, P ^a   Nicolson, M ^d   Raouf, S ^e   Wheatley, D ^f   Plummer, C ^g  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^d ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^e QUEEN S HOSPITAL   (United Kingdom)

^f ROYAL CORNWALL HOSPITAL   (United Kingdom)

^g FREEMAN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79952349033     PISSN: 17508460     EISSN: None     Source Type: Journal    
DOI: 10.12968/hmed.2010.71.12.670     Document Type: Conference Paper

References (45)

1. Besse B, Lassere SF, Compton P, Huang J, Augustus S, Rohr U-P (2010) Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 16:269-78
2. Burger R, Brady MR, Bookman MA et al (2010) Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study J Clin Oncol 28(18 S):946s (Abstract LBA1)
3. Cassidy J, Saltz L, Van Cutsem E et al (2010) Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of over 6,000 patients in randomized phase II and III studies. J Clin Oncol 28(15 S):3604
4. Cortés J, Pivot X, Schneeweiss A et al (2009) Safety of surgery in patients with locally recurrent or metastatic breast cancer treated with docetaxel plus bevacizumab or placebo in the AVADO phase III study. Cancer Res 69(Suppl 2):113s (abstr 1030)
5. Crinò L, Dansin E, Garrido P et al (2010) Safety and efficacy of firstline bevacizumab-based therapy in advanced non-squamous nonsmall cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 11(8):733-40
6. Dincer M, Altundag K (2006) Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension. Ann Pharmacother 40:2278
7. Eremina V, Sood M, Haigh J et al (2003) Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111:707-16 (Pubitemid 36278589)
8. Escudier B, Pluzanska A, Koralewski P et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma; a randomized, double-blind phase III trial. Lancet 370:2103-11 (Pubitemid 350296300)
9. Escudier B, Bellmunt J, Negrier S et al (2010) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28(13):2144-50
10. Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733-40
11. Gerber HP (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65(3):671-80
12. Giantonio BJ, Catalano PJ, Meropol NJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-44 (Pubitemid 46733080)
13. Hambleton J, Novotny WF, Hurwitz H et al (2004) Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation. J Clin Oncol 22 (14 S): 3528
14. Hambleton J, Skillings J, Kabbinavar F et al (2005) Safety of low-dose aspirin (ASA) in a pooled analysis of 3 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 23 (16 S): 3554
15. Hood JD, Meininger CJ, Ziche M et al (1998) VEGF upregulates ecNOS message protein and NO production in human endothelial cells. Am J Physiol 274: H1054-8
16. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-42 (Pubitemid 38702844)
17. Johnson DH, Fehrenbacher L, Novotny WF et al (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22(11):2184-91 (Pubitemid 41095154)
18. Katoh M, Egashira K, Mitsui T, Chishima S, Takeshita A, Narita H (2000) Angiotensin-converting enzyme inhibitor prevents plasminogen activator inhibitor-1 expression in a rat model with cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis. J Mol Cell Cardiol 32(1):73-83 (Pubitemid 30064306)
19. Kilickap S, Abali H, Celik I (2003) Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol 21(18):3542
20. Kozloff M, Yood MU, Berlin J et al (2009) Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRITE observational cohort study. Oncologist 14(9):862-70
21. Levy CF, Oo KZ, Fireman F et al (2009) Reversible posterior leukoencephalopathy syndrome in a child treated with bevacizumab. Pediatr Blood Cancer 52(5):669-71
22. Miles D (2008) Management of toxicity in patients receiving therapy with bevacizumab. Eur J Cancer Suppl 6:29-39
23. Miles DW, Chan A, Dirix LY et al (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28(20):3239-47
24. Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-76
25. National Cancer Institute (1998) Cancer Therapy Evaluation Program Common Toxicity Criteria. Version 2.0. http://ctep. cancer.gov (accessed 22 November 2010)
26. National Cancer Institute (2006) Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events. Version 3.0. http://ctep. cancer.gov (accessed 22 November 2010)
27. National Heart, Lung, and Blood Institute (2004) The seventh report of the Joint National Committee on Prevention, Detection, evaluation, and treatment of high blood pressure. U. S. Department of Health and Human Services. NIH Publication No. 04-5230. www.nhlbi.nih. gov/guidelines/hypertension/jnc7full.pdf (accessed 22 November 2010)
28. National Institute for Clinical Excellence (2006) Hypertension. Management of hypertension in adults in primary care. Clinical Guideline 34. http://egap. evidence.nhs.uk/CG34 (accessed 19 September 2010)
29. Perren T, Swart AM, Pfisterer J et al (2010) ICON7: a phase III randomised gynaecologic cancer intergroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC). Ann Oncol 21 (Suppl 8): viii2
30. Reck M, von Pawel J, Zatloukal P et al (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 27(8):1227-34
31. Reck M, von Pawel J, Zatloukal P et al (2010) Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 21(9):1804-9
32. ® Summary of Product Characteristics. www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000582/ human-med-000663.jsp&murl=menus/medicines/medicines.jsp&mid= WC0b01ac058001d124 (accessed 19 September 2010)
33. Saltz LB, Clarke S, Diaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26(12):2013-19
34. Sandler A, Gray R, Perry MC et al (2006a) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542-50 (Pubitemid 44917502)
35. Sandler AB, Johnson DH, Brahmer J et al (2006b) Retrospective study of clinical and radiographic risk factors associated with early onset, severe pulmonary hemorrhage in bevacizumab-treated patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 24 (18 S): 7068
36. Scappaticci FA, Fehrenbacher L, Cartwright T et al (2005) Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91(3):173-80 (Pubitemid 41254420)
37. Scappaticci FA, Skillings JR, Holden SN et al (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99:1232-9 (Pubitemid 47299901)
38. Schneider BP, Wang M, Radovich M et al (2008) Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26(28):4672-8
39. Schrijvers BF, Flyvbjerg A, De Vriese AS (2004) The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 65(6):2003-17 (Pubitemid 38669987)
40. Shah-Khan FM, Pinedo D, Shah P (2007) Reversible posterior leukoencephalopathy syndrome and anti-neoplastic agents: a review. Oncol Rev 1:152-61
41. Smith IE, Pierga JY, Biganzoli L et al (2010) First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients. Ann Oncol Sep. 4 [Epub ahead of print]
42. Thomas MC, Walker RJ, Yun K (1998) Noradrenaline-producing renal cell carcinoma: a unique cause of endocrine hypertension. Nephrol Dial Transplant 13:1811-14 (Pubitemid 28306817)
43. Van Cutsem E, Rivera F, Berry S et al (2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 20(11):1842-7
44. Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30):4722-9 (Pubitemid 350086473)
45. Wardley A, Lohrisch G, Joy AA et al (2009) Effect of anticoagulation therapy on bleeding and thromboembolic events in the AVADO phase III study of docetaxel ± bevacizumab in metastatic or inoperable locally recurrent breast cancer. Cancer Res 69 (Suppl 2):114s (Abstract 1035)